Intel: Financial Recovery Masks Unfinished Tech Turnaround

What happened

Intel's stock has rallied 401% over the past year on hopes of a turnaround driven by AI server demand and 18A process progress, but the financial recovery masks a lack of fundamental technological redemption. In Q1 2026, Intel's data center revenue grew 22% year-over-year, but that growth came entirely from higher average selling prices—volumes actually declined 5% as supply constraints and product mix favored price over unit recovery. Meanwhile, Intel's foundry business remains a heavy drag, posting a $2.4 billion operating loss on $5.4 billion in revenue, with external foundry revenue only $174 million and substantially all output still captive to Intel's own products. Management's cautious Q2 guidance of $0.20 EPS and 39% gross margin reflects the ongoing cost headwind from ramping 18A production, and the company still lacks substantive external design commitments for the next-generation 14A node. The newly published analysis downgrades Intel from a previous rating, arguing that the stock's recent price now prices in a technological renaissance that has not yet materialized, leaving it vulnerable to disappointment if foundry monetization fails to convert narrative into earnings.

Implication

Intel's strategic assets in x86 CPUs and U.S. manufacturing are real, but the stock's current valuation at over 40x EV/EBITDA implies a successful foundry turnaround that is still unproven. Without visible 14A commitments and gross margin recovery above 42%, the downside risk to $70 (the bear case) remains material. Investors should monitor Q2 results on July 23 and seek evidence that DCAI volumes are turning positive and that external foundry revenue is accelerating beyond the Altera tailwind.

Thesis delta

The new article reinforces the DVM's caution that the market is discounting technological turnaround without evidence. The key shift is that the financial renaissance narrative may be peaking, while the technological redemption story remains incomplete. This tilts the risk-reward toward the bear case, suggesting a higher probability of reversion to the DVM's base case of $105 or lower.